|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1260851489 |
| 003 |
OCoLC |
| 005 |
20231120010555.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
210721s2021 mau o 001 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d OCLCO
|d OCLCF
|d OCLCQ
|d SFB
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|z 9780128246160
|q (print)
|
| 035 |
|
|
|a (OCoLC)1260851489
|
| 050 |
|
4 |
|a RB40
|
| 082 |
0 |
4 |
|a 616.07/56
|2 23
|
| 245 |
0 |
0 |
|a Advances in clinical chemistry.
|n Volume 103 /
|c edited by Gregory S. Makowski.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press, is an imprint of Elsevier,
|c 2021.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed July 21, 2021).
|
| 505 |
0 |
|
|a Intro -- Advances in Clinical Chemistry -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Autoantibodies to tumor-associated antigens in lung cancer diagnosis -- 1. Introduction -- 2. TAAs and TAAbs -- 3. Common technologies to identify TAAs in LC -- 3.1. SEREX -- 3.2. SERPA -- 3.3. Protein microarray -- 4. Major issues for identifying TAAs in cancer diagnosis -- 5. Development of TAAbs as biomarkers in LC diagnosis -- 5.1. Diagnostic performance of single TAAbs for LC -- 5.2. Diagnostic value of TAAbs panels for LC diagnosis -- 5.3. Early detection of TAAbs in LC at pre-clinical stage -- 6. Combination of TAAbs with other indicators in LC detection -- 7. The prognostic value of TAAbs in LC -- 8. Conclusion and future perspectives -- Acknowledgment -- References -- Chapter Two: Extracellular vesicles in cardiovascular disease -- 1. Introduction -- 2. Discovery and nomenclature of EVs -- 3. EVs as a potential source for biomarker discovery in cardiovascular disease -- 3.1. Extracellular vesicle counts -- 3.2. Extracellular vesicle contents -- 3.2.1. Extracellular vesicle proteins -- 3.2.2. Extracellular vesicle lipids -- 3.2.3. Extracellular vesicle nucleic acids -- 4. Potential of EVs as therapeutics in cardiovascular disease -- 4.1. Preclinical testing of EVs as therapeutics in CVD -- 4.1.1. Atherosclerosis -- 4.1.2. Myocardial infarction -- 4.1.3. Stroke -- 4.2. Clinical translation -- 5. Potential of EVs as drug delivery systems in cardiovascular disease -- 5.1. Atherosclerosis -- 5.2. Myocardial infarction -- 5.3. Stroke -- 6. Current methods for the isolation of naturally secreted EVs -- 6.1. Differential ultracentrifugation -- 6.2. Density gradient ultracentrifugation -- 6.3. Immunoaffinity (monoclonal antibody based) method -- 6.4. Ultrafiltration -- 6.5. Size exclusion chromatography -- 6.6. Polymer precipitation.
|
| 650 |
|
0 |
|a Clinical chemistry.
|
| 650 |
|
2 |
|a Chemistry, Clinical
|0 (DNLM)D002624
|
| 650 |
|
6 |
|a Chimie clinique.
|0 (CaQQLa)201-0016714
|
| 650 |
|
7 |
|a Clinical chemistry
|2 fast
|0 (OCoLC)fst00864330
|
| 700 |
1 |
|
|a Makowski, Gregory S.
|q (Gregory Stephen),
|e editor.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00652423/103
|z Texto completo
|
